- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 10.34 Exhibit 10.34
- 10.35 Exhibit 10.35
- 10.36 Exhibit 10.36
- 10.37 Exhibit 10.37
- 10.38 Exhibit 10.38
- 10.39 Exhibit 10.39
- 10.40 Exhibir 10.40
- 10.41 Exhibit 10.41
- 10.42 Exhibit 10.42
- 10.43 Exhibit 10.43
- 10.44 Exhibit 10.44
- 10.45 Exhibit 10.45
- 21.1 Exhibit 21.1
- 23.3 Consent of Independent Registered Public Accounting Firm
- 23.4 Exhibit 23.4
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- 99.9 Exhibit 99.9
- 99.10 Exhibit 99.10
- 99.11 Exhibit 99.11
- 14 Apr 21 EFFECT Notice of effectiveness
- 13 Apr 21 424B3 Prospectus supplement
- 9 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
30 Mar 21 S-4 Registration of securities issued in business combination transactions
Exhibit 99.7
Consent of Person Named as About to Become Director
March 29, 2021
Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the Registration Statement on Form S-4 of Obalon Therapeutics, Inc., and all amendments thereto (the “Registration Statement”), and any related prospectus filed pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended, or related proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended (including any amendments or supplements thereto), as a person anticipated to become a director of Obalon Therapeutics, Inc. upon completion of the merger described therein, and to the filing of this consent as an exhibit to the Registration Statement.
Sincerely, | |
/s/ Bart Bandy | |
Name: Bart Bandy |